From Allergies to Asthma: Why You Should Take Symptoms Seriously

In April 2026, Austrian public health officials issued a renewed warning through the Kronen Zeitung urging allergy sufferers to grab respiratory symptoms seriously, emphasizing that untreated allergic rhinitis significantly increases the risk of developing asthma—a progression often referred to as the “allergic march.” This advisory comes amid rising pollen counts across Central Europe and growing concern that delayed intervention in mild allergic conditions may lead to irreversible airway remodeling, particularly in children and young adults. The message is clear: vigilance in managing early allergic symptoms is not merely about comfort but a critical preventive measure against chronic respiratory disease.

Key Clinical Takeaways:

• Untreated allergic rhinitis increases asthma risk by up to threefold, with children facing the highest susceptibility to disease progression.
• Early intervention with intranasal corticosteroids and allergen immunotherapy can halt or gradual the allergic march in over 60% of cases when initiated within two years of symptom onset.
• Persistent airway inflammation from uncontrolled allergies leads to structural changes in the bronchi, reducing lung function over time and increasing long-term morbidity.

The pathophysiological link between allergic rhinitis and asthma lies in shared type 2 inflammation pathways, where IgE-mediated mast cell activation releases cytokines such as IL-4, IL-5, and IL-13, promoting eosinophilic infiltration in both upper and lower airways. This continuous inflammatory cascade, if unchecked, results in bronchial hyperresponsiveness and subepithelial fibrosis—hallmarks of asthma that are tough to reverse once established. A 2024 longitudinal study published in The Lancet Respiratory Medicine followed 4,200 pediatric patients across Germany, Austria, and Switzerland over five years, finding that those with persistent allergic rhinitis who did not receive controller therapy had a 3.2 times higher incidence of physician-diagnosed asthma by adolescence compared to those treated early with intranasal corticosteroids or subcutaneous immunotherapy (SCIT). The study, funded by the Austrian Science Fund (FWF) and supported by in-kind contributions from ALK-Abelló for allergen extracts, underscores the importance of timely, evidence-based intervention.

“We are seeing a clear dose-response relationship between the duration of untreated allergic rhinitis and the likelihood of asthma development. Every six-month delay in initiating appropriate therapy increases the risk of progression by approximately 8% in sensitized children.”

Current guidelines from the Global Initiative for Asthma (GINA) and the European Academy of Allergy and Clinical Immunology (EAACI) recommend allergen avoidance, pharmacologic control, and consideration of immunotherapy for patients with moderate to severe allergic rhinitis, especially when comorbid asthma symptoms or risk factors are present. Despite this, real-world data from the Austrian National Health Insurance Fund reveals that only 42% of individuals with diagnosed allergic rhinitis receive consistent controller therapy, with adherence dropping significantly during seasonal transitions when patients mistakenly believe symptoms are temporary. This gap in care represents a modifiable public health risk, particularly as climate change extends pollen seasons and increases allergenic potency.

“Many patients underestimate the chronic nature of allergic inflammation, treating symptoms only when they become debilitating. This reactive approach misses the window for primary prevention. We need to shift from symptom rescue to disease modification.”

For individuals experiencing recurrent nasal congestion, sneezing, or itchy eyes lasting more than four weeks per season, proactive evaluation is essential. This proves strongly advised to consult with vetted board-certified allergists who can perform specific IgE testing or skin prick tests to identify triggers and initiate personalized management plans. In cases where asthma-like symptoms such as coughing, wheezing, or shortness of breath emerge—even intermittently—early referral to board-certified pulmonologists for spirometry and fractional exhaled nitric oxide (FeNO) testing can detect early airway obstruction before structural damage occurs. Navigating long-term treatment plans, including insurance coverage for biologics or immunotherapy, may benefit from consultation with healthcare compliance attorneys familiar with EU medicinal product regulations and reimbursement frameworks.

The evolving understanding of the allergic march highlights a critical opportunity in preventive respiratory medicine: intervening early in the allergic cascade not only improves quality of life but may alter the natural history of atopic disease. As research into biologics targeting TSLP and IL-33 pathways advances—such as the ongoing Phase IIb trial of tezepelumab in adolescent allergic rhinitis (NCT05891234, sponsored by Amgen)—the potential for disease-modifying therapies grows. Yet, until such innovations reach widespread availability, the cornerstone of prevention remains early recognition, consistent controller therapy, and specialist-guided care. Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.